Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCrans, René A. J.-
dc.contributor.authorWouters, Elise-
dc.contributor.authorValle León, Marta-
dc.contributor.authorTaura, Jaume-
dc.contributor.authorMassari, Caio M.-
dc.contributor.authorFernández Dueñas, Víctor-
dc.contributor.authorStove, Christophe P.-
dc.contributor.authorCiruela Alférez, Francisco-
dc.descriptionA corrigendum was published at
dc.description.abstractParkinson's disease (PD) is a neurodegenerative disorder characterized by motor control deficits, which is associated with the loss of striatal dopaminergic neurons from the substantia nigra. In parallel to dopaminergic denervation, there is an increase of acetylcholine within the striatum, resulting in a striatal dopaminergic-cholinergic neurotransmission imbalance. Currently, available PD pharmacotherapy (e.g., prodopaminergic drugs) does not reinstate the altered dopaminergic-cholinergic balance. In addition, it can eventually elicit cholinergic-related adverse effects. Here, we investigated the interplay between dopaminergic and cholinergic systems by assessing the physical and functional interaction of dopamine D2 and muscarinic acetylcholine M1 receptors (D2R and M1R, respectively), both expressed at striatopallidal medium spiny neurons. First, we provided evidence for the existence of D2R-M1R complexes via biochemical (i.e., co-immunoprecipitation) and biophysical (i.e., BRET1 and NanoBiT®) assays, performed in transiently transfected HEK293T cells. Subsequently, a D2R-M1R co-distribution in the mouse striatum was observed through double-immunofluorescence staining and AlphaLISA® immunoassay. Finally, we evaluated the functional interplay between both receptors via behavioral studies, by implementing the classical acute reserpine pharmacological animal model of experimental parkinsonism. Reserpinized mice were administered with a D2R-selective agonist (sumanirole) and/or an M1R-selective antagonist (VU0255035), and alterations in PD-related behavioral tasks (i.e., locomotor activity) were evaluated. Importantly, VU0255035 (10 mg/kg) potentiated the antiparkinsonian-like effects (i.e., increased locomotor activity and decreased catalepsy) of an ineffective sumanirole dose (3 mg/kg). Altogether, our data suggest the existence of putative striatal D2R/M1R heteromers, which might be a relevant target to manage PD motor impairments with fewer adverse effects.-
dc.format.extent13 p.-
dc.publisherFrontiers Media-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofFrontiers in Pharmacology, 2020, vol. 11, p. 194-
dc.rightscc-by (c) Crans, René A. J. et al., 2020-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationMalaltia de Parkinson-
dc.subject.classificationMalalties neurodegeneratives-
dc.subject.classificationReceptors neurals-
dc.subject.otherParkinson's disease-
dc.subject.otherNeurodegenerative Diseases-
dc.subject.otherNeural receptor-
dc.titleStriatal dopamine D2-muscarinic acetylcholine M1 receptor-receptor interaction in a model of movement disorders-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
700499.pdfOriginal Article1.16 MBAdobe PDFView/Open
728205.pdfCorrigendum681.95 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons